ACADEMIA
Japan Hypertension Society to Soon Report VART Paper Retraction in Publication
The Japanese Society of Hypertension will soon announce the retraction of the main paper for a now-discredited Diovan (valsartan) study in its journal Hypertension Research, bringing to an end a series of actions it has taken over questions raised for…
To read the full story
Related Article
- Japan Hypertension Society to Retract Diovan Paper on VART Study
August 16, 2016
ACADEMIA
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





